Massachusetts-based biotechnology firm Biogen and its Tokyo-based partner Eisai are seeking a speedy approval from the U.S. Food and Drug Administration for a second Alzheimer’s disease drug, lecanemab. 

Novartis reported second-quarter 2021 financials with net sales growing 15 percent to $12.96 billion. The company also reported on its Covid-19 vaccine production with CureVac and some pipeline updates.

Amryt inked an all-stock acquisition deal with Chiasma. The combined company will focus on rare and orphan diseases with three marketed products and a strong development pipeline.

Merck & Co. Inc. said on April 29 the company would take a bigger hit to sales during 2021 than previously expected due to a resurgence in Covid-19 cases that has hurt demand for drugs that need to be given by doctors.

Bristol Myers Squibb Co. reported lower-than-expected first-quarter profit on April 29 as sales of the company’s high margin cancer drugs Revlimid and Opdivo fell short of Wall Street estimates.

Roche culled two more Phase II Covid-19 programs, as announced in the Swiss pharma giant’s first-quarter 2021 financial report.

BioSpace reviewed the third-quarter 2020 financial announcements from some of the biopharma industry’s leading players.

Five years after the company’s portfolio bottomed out, Bristol-Myers Squibb markets three of the world’s six best-selling pharma brands.

W2O reported 2019 revenue increased by 26 percent to $223 million from $177 million in 2018 and improved operating profit.

Teva Pharmaceutical’s deutetrabenazine for the treatment of tics in pediatric patients with moderate to severe Tourette Syndrome did not meet the primary endpoint in the Phase II/III ARTISTS 1 and Phase III ARTISTS 2 trials.